6 Molecular characterization of macrolide- and multidrug-resistant Streptococcus pyogenes isolated from adult patients in Barcelona, Spain (1993-2008)

7 A restoration genetics guide for coral reef conservation

8 A cluster of ecthyma outbreaks caused by a single clone of invasive and highly infective Streptococcus pyogenes

9 Helicobacter pylori Primary Antibiotic Resistance in 2015 in Morocco: A Phenotypic and Genotypic Prospective and Multicenter Study

10 Impact of rotavirus vaccination on rotavirus and all-cause gastroenteritis in peri-urban Kenyan children

11 The immune response to a meningococcal polysaccharide vaccine in an African village

12 Population Impact and Effectiveness of Monovalent Rotavirus Vaccination in Urban Malawian Children 3 Years After Vaccine Introduction: Ecological and Case-Control Analyses

13 Factors affecting the evolution of bleaching resistance in corals

14 Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group

15 Boceprevir for untreated chronic HCV genotype 1 infection

16 Effectiveness of Monovalent Rotavirus Vaccine After Programmatic Implementation in Botswana: A Multisite Prospective Case-Control Study

17 Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco

18 Human rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial

19 Update of rotavirus strains circulating in Africa from 2007 through 2011

20 Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine

21 The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

22 High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections

23 Accuracy of phenotypic and genotypic testing for identification of Streptococcus pneumoniae and description of Streptococcus pseudopneumoniae sp. nov

24 Possible interruption of measles virus transmission, Uganda, 2006-2009

25 asociación y efectos de interacción en los genes agt, agtr1, ace, adrb2, drd1, add1, add2, atp2b1, tbxa2r y ptgs2 sobre la hipertensión en la población antioqueña

26 efecto del genotipo y de la dieta en la digestibilidad rectal de nutrientes y salida fecal de cerdos criollo cubano

27 association of il-18 gene polymorphism at position -137g / c with vaginal candidiasis

28 a response to letter to the editor: a genetic-based algorithm for personalized resistance training

29 male gametophytic screening of citrus genotypes for salt stress tolerance

30 Epidemiological investigation of vaginal Saccharomyces cerevisiae isolates by a genotypic method

31 Different region analysis for genotyping Yersinia pestis isolates from China

32 Use of tall fescue EST-SSR markers in phylogenetic analysis of cool-season forage grasses

33 Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals

34 Mutations, mutation rates, and evolution at the hypervariable VNTR loci of Yersinia pestis

35 Epidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype

36 Comparison of extraintestinal pathogenic Escherichia coli strains from human and avian sources reveals a mixed subset representing potential zoonotic pathogens

37 Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis

38 Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial

39 Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas

40 Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

41 Yersinia pestis lineages in Mongolia

42 Similarity between human and chicken Escherichia coli isolates in relation to ciprofloxacin resistance status

43 Decrease in macrolide resistance and clonal instability among Streptococcus pyogenes in Portugal

44 Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

45 Nosocomial transmission of Saccharomyces cerevisiae in bone marrow transplant patients

46 Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy

47 Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study

48 The diploid genome sequence of an individual human

49 Insight into microevolution of Yersinia pestis by clustered regularly interspaced short palindromic repeats

50 Mutations in proteasome subunit β type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity

51 Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

52 Emerging avian pathogenic Escherichia coli strains belonging to clonal groups O111:H4-D-ST2085 and O111:H4-D-ST117 with high virulence-gene content and zoonotic potential

53 Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies

54 Sequence and structural variation in a human genome uncovered by short-read, massively parallel ligation sequencing using two-base encoding

55 Mice lacking ghrelin receptors resist the development of diet-induced obesity

56 In vivo requirements for rDNA chromosome condensation reveal two cell-cycle-regulated pathways for mitotic chromosome folding

57 Population structure, virulence potential and antibiotic susceptibility of uropathogenic Escherichia coli from Northwest England

58 Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C

59 Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays

60 Avian-pathogenic Escherichia coli strains are similar to neonatal meningitis E. coli strains and are able to cause meningitis in the rat model of human disease

61 A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec

62 Ancient human genome sequence of an extinct Palaeo-Eskimo

63 Molecular epidemiology of impetiginous group A streptococcal infections in aboriginal communities of northern Australia

64 Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

65 Clonal relatedness of erythromycin-resistant Streptococcus pyogenes isolates in Germany

66 Tandem repeats analysis for the high resolution phylogenetic analysis of Yersinia pestis

67 Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15

68 Sofosbuvir for previously untreated chronic hepatitis C infection

69 A genome-wide survey of the prevalence and evolutionary forces acting on human nonsense SNPs

70 Comparison of Escherichia coli isolates implicated in human urinary tract infection and avian colibacillosis

71 Species identification and virulence attributes of Saccharomyces boulardii (nom. inval.)

72 Accurate whole human genome sequencing using reversible terminator chemistry

73 Chromosomal rearrangement features of Yersinia pestis strains from natural plague foci in China

74 Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada

75 Relationship Between the CYP2C19 Phenotype Using the Voriconazole-to-Voriconazole N-Oxide Plasma Concentration Ratio and Demographic and Clinical Characteristics of Japanese Patients With Different CYP2C19 Genotypes.

76 Translocation of elements and sugars in wheat genotypes at vegetative and generative stages under continuous selenium exposure.

77 HPV genotype prevalence and distribution during 2009-2018 in Xinjiang, China: baseline surveys prior to mass HPV vaccination.

78 Quantitative proteomics identify an association between extracellular matrix degradation and immunopathology of genotype VII Newcastle disease virus in the spleen in chickens.

79 PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian population.

80 Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations

81 Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype

82 Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial

83 Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

84 Evaluation of the GenoType MTBDRplus and MTBDRsl for the detection of drug-resistant Mycobacterium tuberculosis on isolates from Beijing, China

85 Overview of pneumococcal serotypes and genotypes causing diseases in patients with chronic obstructive pulmonary disease in a Spanish hospital between 2013 and 2016

86 Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

87 Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

88 Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

89 Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients

90 Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations

91 Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations

92 Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype

93 Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial

94 Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

95 Evaluation of the GenoType MTBDRplus and MTBDRsl for the detection of drug-resistant Mycobacterium tuberculosis on isolates from Beijing, China

96 Overview of pneumococcal serotypes and genotypes causing diseases in patients with chronic obstructive pulmonary disease in a Spanish hospital between 2013 and 2016

97 Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

98 Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

99 Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

100 Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients

101 Evaluating Performance of Sesame (Sesamum indicum L.) Genotypes in Different Growing Seasons in Northern Ethiopia

Keyword Connections

Journals

Research Groups

Bibliographies